Last reviewed · How we verify
Maxigesic IV
Maxigesic IV combines paracetamol and ibuprofen to provide analgesia and anti-inflammation through dual inhibition of prostaglandin synthesis and central pain modulation.
Maxigesic IV combines paracetamol and ibuprofen to provide analgesia and anti-inflammation through dual inhibition of prostaglandin synthesis and central pain modulation. Used for Acute postoperative pain, Moderate to severe pain requiring multimodal analgesia.
At a glance
| Generic name | Maxigesic IV |
|---|---|
| Also known as | Maxigesic |
| Sponsor | AFT Pharmaceuticals, Ltd. |
| Drug class | Fixed-dose combination analgesic/NSAID |
| Target | Prostaglandin synthesis inhibitors (COX-1, COX-2, and central pain pathways) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Maxigesic IV is a fixed-dose combination of paracetamol (acetaminophen) and ibuprofen administered intravenously. Paracetamol acts primarily through central inhibition of prostaglandin synthesis and modulation of pain pathways, while ibuprofen is a non-selective NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin production peripherally and centrally. The combination provides synergistic analgesic and anti-inflammatory effects with potentially lower doses of each agent than used individually.
Approved indications
- Acute postoperative pain
- Moderate to severe pain requiring multimodal analgesia
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Injection site reactions
Key clinical trials
- The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement (NA)
- Analgesic Efficacy of Maxigesic in Breast Cancer Surgery (NA)
- Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section (PHASE4)
- Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
- Maxigesic® IV Phase 3 Exposure Study (PHASE3)
- Maxigesic IV Phase 3 Bunionectomy Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maxigesic IV CI brief — competitive landscape report
- Maxigesic IV updates RSS · CI watch RSS
- AFT Pharmaceuticals, Ltd. portfolio CI